Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period

NCT01683266 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01683266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2012
Completion date
March 31, 2014
Enrollment
549 (actual)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus